With follow-up experiments, the tumor suppressor PDCD4 was validated as a downstream phosphorylation target of CXCL12 signaling in all CLL patient cells examined (n = 10) and HSP27 was similarly validated in a subset of CLL patients (∼25%). The gene discussed is CXCL12; the disease is B-cell chronic lymphocytic leukemia.